Parfenov Vladimir A, Ostroumova Olga D, Ostroumova Tatiana M, Kochetkov Alexey I, Fateeva Victoria V, Khacheva Kristina K, Khakimova Gulnara R, Epstein Oleg I
Department of Neurology, Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation.
Laboratory of Clinical Pharmacology and therapy, Federal State Budgetary Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation, Russian Clinical and Research Center of Gerontology, Moscow, Russia.
Neuropsychiatr Dis Treat. 2019 May 21;15:1381-1402. doi: 10.2147/NDT.S197032. eCollection 2019.
Vascular cognitive impairment (VCI) and vascular dementia are the most common forms of cognitive disorder associated with cerebrovascular disease and related to increased morbidity and mortality among the older population. Growing evidence suggests the contribution of blood-pressure variability, cardiac arrhythmia, hyperactivation of the renin-angiotensin-aldosterone system, endothelial dysfunction, vascular remodeling and stiffness, different angiopathies, neural tissue homeostasis, and systemic metabolic disorders to the pathophysiology of VCI. In this review, we focus on factors contributing to cerebrovascular disease, neurovascular unit alterations, and novel approaches to cognitive improvement in patients with cognitive decline. One of the important factors associated with the neuronal causes of VCI is the S100B protein, which can affect the expression of cytokines in the brain, support homeostasis, and regulate processes of differentiation, repair, and apoptosis of the nervous tissue. Since the pathological basis of VCI is complex and diverse, treatment affecting the mechanisms of cognitive disorders should be developed. The prospective role of a novel complex drug consisting of released-active antibodies to S100 and to endothelial NO synthase in VCI treatment is highlighted.
血管性认知障碍(VCI)和血管性痴呆是与脑血管疾病相关的最常见认知障碍形式,并且与老年人群发病率和死亡率增加有关。越来越多的证据表明,血压变异性、心律失常、肾素 - 血管紧张素 - 醛固酮系统的过度激活、内皮功能障碍、血管重塑和僵硬、不同的血管病变、神经组织稳态以及全身代谢紊乱对VCI的病理生理学有影响。在本综述中,我们关注导致脑血管疾病的因素、神经血管单元改变以及认知功能下降患者认知改善的新方法。与VCI神经元病因相关的重要因素之一是S100B蛋白,它可以影响大脑中细胞因子的表达,维持内环境稳定,并调节神经组织的分化、修复和凋亡过程。由于VCI的病理基础复杂多样,应开发影响认知障碍机制的治疗方法。强调了一种由针对S100和内皮型一氧化氮合酶的释放活性抗体组成的新型复合药物在VCI治疗中的潜在作用。